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CHAPTER 1: INTRODUCTION
Cystic Fibrosis
Cystic fibrosis (CF) is the most common, fatal autosomal recessive disease, with a disease
frequency of 1 in 2000 live births and a carrier rate of approximately 5% in the Caucasian
population [1]. CF can be characterized as a failure of exocrine tissue in which there is an
aberration in the regulation of epithelial Cl- channel which is associated with pathophysiology of
the disease [2]. The major clinical signs and symptoms of CF include chronic pulmonary disease,
pancreatic exocrine insufficiency, intestinal disease, and an increased sweat chloride
concentration. With the many major developments in the treatment of CF patients, most of the
morbidity and mortality is due to lung disease. The lungs of CF patients become colonized with
bacteria which leads to repeated pulmonary infections. The repeated pulmonary infections lead to
chronic airway and systemic inflammation, submucosal gland hypertrophy, excessive mucus
secretion, impaired mucociliary clearance, and plugging of the small airways that cause
progressive bronchiectasis, which eventually leads to lung failure [3-5].
CFTR
CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator
(CFTR), which is a member of the ATP-binding cassette (ABC) transporter superfamily. CFTR is
a cAMP-regulated chloride channel found at the apical membranes of most epithelial cells lining
the airway and other organs [6]. There are more than 2000 identified CFTR mutations in the CFTR
gene (http://www.genet.sickkids.on.ca/cftr/). The most common mutation amongst CF patients is
the deletion of the phenylalanine residue at position 508 (CFTR-F508del) [7], which is located in
the nucleotide binding domain 1 (NBD1). More than 90% of CF patients have at least one copy of
the CFTR-F508del (F508del) allele. F508del is unable to achieve a native, folded state that is
required for the protein to export from the endoplasmic reticulum (ER) to the apical membrane of
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epithelial cells [8], instead the mutant protein is retained in the ER region. There are several lines
of evidence that demonstrate the F508del is a folding/processing mutation. Firstly, the F508del
mutation is temperature-sensitive, where cells that were incubated at a lower temperature (27ºC)
lead to the expression of F508del at the plasma membrane [9, 10]. Secondly, cells cultured with
high concentrations (>1M) of chemical chaperones, such as glycerol, restores the function of
F508del at the plasma membrane [11]. Thirdly, there is assistance of several molecular chaperones
on the functional expression of CFTR, whose interactions with F508del is prolonged compared to
wild-type (WT) CFTR [12-14]. Fourthly, in vitro studies of denaturation and refolding of CFTR
fragments corresponding to the first nucleotide binding domain, where F508del is located, have
shown that its folding is energetically complex, and the ability of NBD1 with the F508del mutation
to reach a native, folded state is impaired compared to the WT NBD1 [15].
When there is a delay in the completion of the native conformation, the CFTR protein is
thought to maintain prolonged interaction with molecular chaperones [12-14], which may target
the protein for degradation by mechanisms that monitor the ER for misfolded or incompletely
complexed proteins. It takes about 10 minutes [16] for CFTR to be created in most cell types, and
the assembly of CFTR into a channel is inefficient, where about 99% of newly synthesized
F508del is degraded by the ubiquitin proteasome system (UPS), and approximately 60% of the
WT-CFTR protein is degraded by the same system [17, 18]. There is substantial evidence
demonstrating that misfolded CFTR polypeptides are substrates for the UPS. Firstly, inhibition of
the activity of the proteasome by MG-132 cause the accumulation of polyubiquitinated CFTR that
can be detected as a characteristic ~7kDa ladder [19, 20]. Second, immunoprecipitated CFTR from
cells treated with proteasome inhibitors resulted in a high molecular mass “smear” that is
recognized by a ubiquitin antibody [21]. Third, overexpression of the ubiquitin ligase, CHIP, lead
to CFTR degradation [22]. Fourth, knockdown of ER membrane anchored E3 ligases, RMA1 and
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gp78 using siRNA protect CFTR from degradation [23, 24]. Fifth, Derlin-1/p97-mediated CFTR
protein retrotranslocation from the ER to the cytosol for proteasomal degradation delineates an
early pathway of CFTR degradation [24-26] CFTR is the first mammalian integral membrane
protein to be identified as a substrate for the ubiquitin-proteasome mediated degradation [19, 21],
and is used as a model for many diseases of protein conformation, which account for a diverse set
of pathologic etiologies such as neurodegenerative diseases [27].
CFTR Protein Structure
The CFTR protein consists of 1480 amino acids that is organized into five functional
domains [6, 28]. CFTR has two membrane-spanning domains (TMD1 and TMD2), two nucleotidebinding domains (NBD1 and NBD2), and one regulatory domain (R). TMD1 and TMD2 are
comprised of six transmembrane fragments that form the CFTR channel pore. NBD1 and NBD2
interact with ATP to regulate channel activity opening and closing of the TMDs [29, 30]. Channel
activity is also controlled by the interactions of the R domain with the N-terminal cytosolic region
of TMD1 [6, 31, 32]. NBD1 and NBD2 binds and hydrolyzes ATP, which then causes a
conformational change in TMD1 and TMD2, which eventually allows for the transport of Clacross the cell membrane [33]. Mutations in CFTR can occur in any of the five domains, however,
many of the mutations occur in NBD1, including the F508del mutation. Where the specific
mutation is located on CFTR can affect the formation or function of the CFTR protein. The
domains of CFTR and the connecting sequences that have already been shown to be mutated
include: the N-terminal [34, 35], intracellular loops (ICL) [36-42], extracellular loops (ECL) [4345], transmembrane helixes 1 through 12 [30, 46-49], and the C-terminal domain. Because the
F508del mutation is found on NBD1, this domain has been studied more intensively. The F508del
mutation is found in 90% of CF patients, and this mutation on NBD1 causes the destabilization of
the CFTR protein [50-52] ATP-binding occurs in both NBD1 and NBD2, which than leads to the
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hydrolysis of intracellular ATP to ADP [50, 53]. This leads to conformational changes that allow
the CFTR channel to transition from an open to closed state, therefore controlling the gating
kinetics of the channel. Other NBD1 mutations, such as G542X and G551D, also have aberration
in channel gating [50-52, 54]. The channel activity of CFTR is not only controlled by NBD1 and
NBD2, but also with the R domain. The activation of the CFTR channel is dependent on the
phosphorylation by cAMP-dependent protein kinase A (PKA) [41, 55]. There are reports that
CFTR can be phosphorylated by other protein kinases including protein kinase C (PKC), cyclic
GMP activated protein kinase, Src kinase and casein kinase II [55]. Also, there are multiple
phosphorylation sites on the R domain which can help modulate specific domain-domain
interactions that are stimulated by PKA [41]. Mutations of the R domain, such as D648V, E664X,
E656X, and 2108delA, disrupt R domain function, which results in aberrant gating of the CFTR
channel [56, 57].
CF Classifications
The more than 2000 different CF mutations can be categorized based on the dysfunctions
of CFTR at different levels of maturation and function of the channel. Traditionally, these
mutations were grouped by CFTR function (Classes I, III, IV, and VI) or CFTR processing
(Classes I,II, and V) [58-60].
Class I mutations
Class I mutations include nonsense mutations, splice mutations, or deletions, that
introduces a premature termination codon (PTC), that prevent functional CFTR biosynthesis. 22%
of CF patients have at least one mutation in this class. G542X, W1282X, and, R553X are examples
of Class I mutations.
Class II mutations
Class II mutations include a missense mutation which causes the CFTR protein to be
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produced, however CFTR is misfolded and is degraded by the ER quality control system, keeping
the protein from trafficking to the cell surface. About 90% of CF patients have at least one mutation
in this class. F508del, N1303K, and 1507del are examples of this class of mutation.
Class III mutations
Class III mutations are missense mutations that produces a non-functioning, unstable
protein that can traffic to the cell surface. These types of mutations are also called gating mutations
and about 6% of people with CF have this mutation. Examples of Class III mutations are G551D
and S549N.
Class IV mutations
Class IV mutations include missense mutations which produces a CFTR channel with less
conductance. This conductance is decreased because of an abnormal conformation of the pore,
resulting in aberrant ion flow. These mutations account for about 6% of CF patients. Examples of
this class of mutations include D1152H, R347P, and R117H.
Class V mutations
Class V mutations introduce splicing of promotor defects in the CFTR gene, leading to a
reduced amount of CFTR protein at the cell surface. These mutations affect gene expression, not
the conformational changes of the channel. This class of mutations affects about 5% of individuals
with CF. Examples of these types of mutations include 3849+10kbC‣T, 2789+5G‣A, and A455E.
Class VI mutations
Class VI mutations increase the turnover of CFTR protein at the cell surface. Even though
the CFTR protein is functional, it’s highly unstable at the cell surface and is quickly removed from
the cell surface and degraded by the lysosome. Example of these types of mutations include
rescued F508del, 120del23, N286Y, 4326dellTC, and 4279insA.
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Even though there are more than 2000 mutations of CFTR, there is a lack of correlation
between the genotype and phenotype of CF patients [61]. For example, a study demonstrated that
meconium ileus (MI) only developed in a subset of CF patients. The study showed that non-CFTR
genes contribute to its susceptibility, and the CFTR genotype affects the occurrence of this
complication, where patients with the more severe CFTR variants are at risk for MI. It was
hypothesized that the susceptibility to MI was influenced by specific CFTR genotypes and that the
prevalence of MI can be used to discriminate among severe CFTR mutations [62]. Also, the
pleiotropic defects of a single mutation in the CFTR gene has limited the drug therapy effects of
certain mutants which have been categorized as Class I, II, or II/III [60]. These problems led to
authors proposing in expanding the classification of the major mechanistic categories [6, 28, 63]
which accommodates the complex, combinatorial molecular/cellular phenotypes of CF. The new
classification consists of 31 possible classes of mutations, including the original classes and 26
combination of the original classes [60]. To illustrate this new classification system, F508del is
now classified as Class II-III-VI, where before it was solely Class II. This classification system
was further supported by a study by Vertex Pharmaceutical where they tested 54 missense
mutations and found that 24 of them had both processing and gating defects [64]. This new
classification system is critical in that it allowed individuals for certain mutations to have a broader
reach in the type of therapy that is given. For example, when F508del was classified as only a
Class II mutation, it was thought that only corrector drugs, such as VX-809, could be used for
individuals with this mutation. However, F508del is now classified as Class II-III-VI, which
allowed for a new combinatorial drug therapy called Orkambi, which is a combination of VX-809
(corrector) and VX-770 (potentiator), to be used by individuals with the F508del mutation [65].
CFTR and Endoplasmic Reticulum Associated Degradation (ERAD)
The ER provides mechanisms that facilitate the appropriate folding of newly synthesized
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secretory and integral membrane proteins, and eliminates proteins that are unable to achieve their
native, folded state [66, 67]. The balance of proper folding and disposal of misfolded proteins is
vital for cellular homeostasis. When there is an accumulation of irregular proteins, ER stress is
evoked, along with the unfolded protein response, which induces the expression of ERAD
components to accelerate protein elimination [68, 69]. ERAD is the process in which protein
substrates are polyubiquitinated and travel to the cytosol for protein degradation. ERAD can be
divided into four steps: recognition, retrotranslocation, ubiquitination, and degradation. These
steps include the recognition and the removal of misfolded proteins from the ER, followed by their
cytoplasmic ubiquitination and ubiquitin-dependent proteolysis by the 26S proteasome [70-72].
Protein substrates transiting the ER can be soluble or membrane bound with significant
portions in the lumen, membrane, and cytosol. To achieve specificity, ERAD employs different
mechanisms to monitor protein misfolding. This can be characterized in yeast, in which distinct
E3 complexes define different ERAD pathways [73-75]. Membrane and soluble proteins with
luminal lesions are delivered to the ERAD-L pathway in which the Hrd1p/Hrd3p ligases form a
complex by binding to Der1p via the linker protein Usa1p. Membrane proteins with misfolded
cytoplasmic domains uses the ERAD-C pathway, which are directed to the E3 ligase Doa10p [73].
substrates with misfolded intramembrane domains are subjected to the ERAD-M pathway, which
differs from the ERAD-L pathway by being independent of Usa1p and Der1p. All three pathways
eventually converge at cdc48/AAA p97 ATPase complex [76].
In mammalian cells, the ERAD pathway is more complex. It is poorly understood how
ERAD machinery recognizes misfolded protein in the ER, however, there are three potential
mechanisms. First, molecular chaperones play a central role in the recognition of misfolded
proteins. Examples are Hdj-2 and Aha-1, which are co-chaperones for Hsp70 and Hsp90,
respectively. Hdj-2 recognizes F508del twice as much as WT-CFTR [20], while the knock down
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of Aha-1 by RNA interference results in a significant amount of F508del maturation [77]. Also,
the result that Aha-1 interacts preferentially with CFTR in the region corresponding to the F508del
mutation further supports this mechanism [78]. Second, the ubiquitin ligase, CHIP, targets
defective proteins whose cytoplasmic domains are recognized by the cytoplasmic chaperones of
the Hsp70-Hsp90 family [12-14]. Third, Derlin-1 mediated CFTR degradation plays a role in
recognizing misfolded membrane or transmembrane proteins [24-26].
After the recognition process, misfolded proteins are transported to the cytoplasm for
proteasomal degradation, a process which is called dislocation or retrotranslocation [79, 80]. The
retrotranslocation machinery consists of p97 (VCP), Derlin-1 and valosin-containing protein
(VCP)-interacting membrane protein (VIMP) [81]. Derlin-1 may form a retrotranslocation channel
in the ER membrane and it links their recognition of misfolded ER proteins to the ubiquitinmediated proteasomal degradation in the cytosol [81, 82].
Ubiquitin Proteasome System (UPS)
Retrotranslocated proteins are subsequently ubiquitinated by the E1-E2-E3 ubiquitin
cascade system [83]. In mammalian cells, there are two E1 activating enzymes, about 40 E2
conjugating enzymes and about 1000 E3 ubiquitin ligase enzymes have been identified [84]. The
corresponding ubiquitin conjugase (E2) and ligase (E3) have been shown to be specific in the three
different ERAD pathways discussed above [73, 74]. In this system, activation of the ubiquitin
occurs through an ATP-dependent formation of a high energy thioester bond between the active
site cysteine of the E1 activating enzyme [85]. The activated ubiquitin follows the cascade and
binds to the E2 conjugating enzyme. Finally, the E3 ubiquitin ligase binds to the E2-bound
ubiquitin and the protein substrate, in this case the F508del, and promotes the transfer of the
ubiquitin to the substrate [86]. This process occurs several times, where additional ubiquitin
molecules are conjugated to the first ubiquitin molecule, form a polyubiquitin chain that is
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recognized by the 26S proteasome in the cytosol, where degradation of the polyubiquitinated
F508del occurs [87, 88]
The substrate is usually ubiquitinated by an isopeptide bond between the carboxyl end of
ubiquitin and lysine primary amine of the substrate. When the poly-ubiquitin chain is formed,
another ubiquitin forms another isopeptide bond with a lysine residue of the original ubiquitin.
Ubiquitin is a highly conserved 76 amino acid polypeptide that contains seven lysine (K) residues
(K6, K11, K27, K29, K33, K48, and K63). All seven lysine residues can be conjugated together
to form a poly-ubiquitin chain on substrates topologies [89, 90]. Interestingly, the lysine-linked
poly-ubiquitin chains that are formed on F508del seem to be through K11, K48, and K63 linkages,
where K11 and K48 linkage facilitate degradation of F508del and K63 linkages prevent
degradation. These linkages are important because they are believed to be mediated by the E2
conjugating enzymes [90-93]
There are about 1000 E3 ligase enzymes therefore they demonstrate substrate specificity
[68, 94]. While the E3 ligases recognize and bind to the protein substrate, the E2 enzymes catalyzes
the transfer of ubiquitin to the substrate. Because F508del is retained and poly-ubiquitinated in the
ER, there must be ER resident E3 ligases that recognize F508del. Several E3 ligases have been
implicated in F508del degradation including RNF5, CHIP, gp78, Hrd1, Nedd4-2, and RNF185
[95-99] However, other E3 ligases seem to be involved in F508del degradation because previous
studies have demonstrated a significant amount of F508del being degraded even when some of the
above mentioned E3 ligases were silenced. Also, E2 conjugating enzymes may mediate the
different K-linkages that progresses F508del for degradation. Therefore, further studies must
investigate other ER resident E3 ligases and their interacting E2 conjugating enzymes that may
mediate F508 degradation.
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Conclusion
There are still some missing links in the F508del degradation, and the purpose of this part
of the study is to identify early checkpoints in the ubiquitin proteasome system that recognizes
F508del early in its biogenesis in the ER. Previous studies have looked at the degradative
machinery involved in CFTR degradation. However, the ER-resident E3 ligases are poorly
understood in this process, therefore characterizing their role is crucial for understanding the
premature degradation of F508del. Our preliminary data indicate that RNF19B is an E3 ligase that
is involved in F508del degradation. This E3 ligase has and interacting E2 conjugating enzyme,
UBE 2L6. This study will determine if these enzymes mediates the degradation of F508del.
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CHAPTER 2: INTRODUCTION OF CYSTIC FIBROSIS ANIMAL MODELS
CF Animal Models
There have been major progress in understanding CF pathogenesis since the gene was first
cloned in 1989 [7], however, many question remain unanswered, including the pathogenesis of the
disease in different organ and their reaction to different therapies [28, 100]. Cell model systems
have been important in determining underlying mechanisms; however, they are unable to
recapitulate pathogenesis of the disease at complex levels of organs. CF animal models have been
crucial in the understanding of the disease pathogenesis and the development of therapeutics for
the disease [101], however there are many limitations to these models. Some models fail to
reproduce major pulmonary phenotypes that are observed in CF patients or they fail to resolve
pathophysiological question such as the roles of abnormal airway superficial epithelium vs.
submucosal glands (SMGs) in the pathogenesis of CF lung disease [102-107]. Other larger animal
models only live for a short amount of time and/or levy high maintenance costs and require special
care which in turn limits their use for the evaluation of different therapeutic agents [101, 108].
Mouse model
The interruption of the CFTR gene generated a knockout (KO) mice model with no
production of normal CFTR [109]. These models are unable to detect spontaneous colonization of
Staphylococcus aureus, Haemophilus influenza, or Pseudomonas aeruginosa, bacterial species
that cause lung infections in human CF patients [110, 111]. This is due to the fact that mice express
low levels of non-gastric H+/K+ adenosine triphosphatase ATP12A, which helps with the exchange
H+ and K+ ions across the membrane. Therefore, this maintains the pH of the airway surface liquid,
which seems to act as a defense in the airway against infections [112]. The mice model is unable
to further our understanding on how the disease is initiated and the development of infection. Other
differences include insufficient size of the airway and the presence of a non-CFTR calcium-
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activated Cl-channel (CACC) that is not similar to humans [58, 113, 114].
Rat model
The mouse model has many dissimilarities to humans, including that fact the SMGs were
only located at the proximal trachea. The rat model, on the other hand, had SMGs that spread to
the bronchi, which was similar to humans. Therefore, the CFTR KO rat model was developed
[104]. The CFTR KO rats showed congenital tracheal defects and decreased airway surface liquid
in the distal airways, similar to what is observed in humans [104]. However, this model is unable
to spontaneously develop lung disease during the first 6 weeks of life, therefore they are unable to
recapitulate the lung phenotype that is observed in humans.
Zebrafish model
The zebrafish CF model was produced using transgenic zebrafish mutant lines [115]. These
animals were inexpensive to house and showed that CFTR channels respond to agonists and
antagonists, similar to human CFTR. This model was able to demonstrate the importance of CFTR
function in fluid secretion; however, the lung phenotype is not fully elucidated in this model.
Porcine model
Due to the expression of the CACC in mice, the CF pig model was developed because of
their similar airway and lung anatomy to humans. Adeno-associated virus vectors that targeted the
CFTR gene in fibroblasts from fetal pigs and somatic cell nuclear transfer of the cells into oocytes
was used to generate CFTR KO piglets [108, 116, 117]. Interestingly, at birth, the CFTR KO
piglets’ lungs had no sign of pathology [118], however bronchioalveolar lavage fluid (BALF) from
these piglets revealed a large number bacterial species [106, 118] that led to rapid lung infection,
which was more severe than what was seen in human CF patients [106, 119]. Another problem
with the pig model is that it is difficult to study the development lung disease because most of the
CFTR KO pigs die from MI that is present in 100% of these pigs [106, 116, 118, 120, 121]. The
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pig model was able to mimic many of the pathologies that is seen in human CF, however, only a
small population of animals were used because of the difficulty to keep them alive, even after
ileostomy or cecostomy to cure the MI problem [121, 122]. Thus, it would be beneficial for a new
model to provide insight into the pathogenesis of CF.
Ferret model
CFTR KO ferrets were also developed by the same manner as the pig model due to
similarities in lung function and architecture of that of human lungs [123]. The ferret model
revealed similar lung pathologies as in humans in that there was air obstruction, thick mucus
accumulation and inflammation [124]. Similar to what is seen if the pig model, CFTR KO ferrets
developed spontaneous lungs infections after birth, however the lung pathology was more severe
than what is seen in human CF patients [124-127]. Like the pig model, CFTR KO ferrets developed
MI at a higher percentage than humans with CF. These ferrets develop MI at an incidence of 50%
to 100%, and they die within 36 hours due to intestinal obstruction and sepsis [108]. The animals
that do survive the MI will eventually die because of malabsorption. A gut corrected model was
also developed to correct MI in the ferret model, but once again there was difficulty in keeping the
animals alive [125].
Sheep model
The sheep model has been used in studying many respiratory disease such as asthma and
chronic obstructive pulmonary disease (COPD) due to their airways being similar to humans
anatomically and functionally [128, 129]. Therefore, CFTR KO sheep were generated by using the
CRISPR/Cas9 genome editing and somatic cell nuclear transfer methods [103]. Early reports
suggest that the CFTR KO sheep demonstrate severe intestinal obstruction that is similar to human
babies. However, the upkeep of the animal model in unfeasible, therefore a limited number of
laboratories can use these animals.
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Conclusions
The pathogenesis of CF is still undeveloped, despite the many models at our disposal. Cell
culture models have been critical in the development of preclinical trials, however, they are unable
to recapitulate the disease pathophysiology of that can be seen in intact organs [130, 131]. The
mouse model is unable to recapitulate the human lung phenotype, while the pig and ferret models
have a more severe lung phenotype compared to humans. Also, the pig and ferret models are
difficult to keep alive due to the severe intestinal obstructions, therefore studies can only be
performed on few animals at a high cost. Therefore, a new model must be developed that
recapitulates the human lung phenotype that can be studied without the worry of an early death.
We report the generation and the characterization of the CF rabbit model. Table-1 illustrates and
compares rabbits to other animals that have already been developed as major CF models. Rabbit
CFTR consists of 1481 amino acids, similar to the 1480 amino acids for human CFTR. Rabbit
CFTR has ~93% identity to human CFTR, the highest amongst the other animals used to generate
CF animal models. With respect to disease pathogenesis, the rabbit lung has few, if any SMGs and
has an architecture that is similar to human distal airways [132-138]. In this part of the study we
characterize and determine the functional defect of CF rabbits’ airway and lungs.
Table 1: CFTR related characteristics among species
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The overall goal of this project is to determine and delineate underlying mechanisms of the
premature degradation of CFTR-F508del, and to determine if the absence of CFTR in rabbits is
able to recapitulate airway and lung phenotypes seen in human CF patients. Our hypothesis is
that RNF19B and UBE 2L6, proteins part ubiquitin proteasome system, are responsible for the
degradation of F508del, and the absence of CFTR in the rabbit mimics what is seen in human
CF airway and lung.
Specific Aims
Aim 1: Identify early checkpoints in the ubiquitin proteasome system that is involved in F508del
degradation
Previous studies have looked at the degradative machinery involved in CFTR degradation.
However, the ER-resident E3 ligases may serve a role in the ER retained F508del degradation,
therefore, uncovering these proteins and characterizing their role is crucial for understanding the
degradation of F508del. Our preliminary data indicate that the E3 ligase, RNF19B and its
interacting partner, the E2 conjugating enzyme UBE 2L6, is involved in F508del degradation.
Using cell model systems, we will uncover the degradation of F508del by RNF19B and UBE 2L6
through siRNA experiments, overexpression experiments, cycloheximide-chase experiments,
immunohistochemistry, biotinylation experiments, and functional experiments.
Aim 2: Determine the Functional Defect of CFTR Knockout rabbits’ airway
Understanding the molecular mechanism of CFTR degradation is important, however there
are limitations in the in vitro system. Therefore, we used CRISPR/Cas9 gene editing to knockout
(KO) the CFTR gene in the rabbit genome. We must characterize and confirm that this model
mimics the phenotypes that is seen in human CF patients, especially the lung phenotype. Once this
is accomplished, we will use this model to pursue pharmacologically targets that we find in the
first aim. We will use electrophysiological, biochemical and pathological experiments on these
animals to characterize our model.
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CHAPTER 3: DEGRADATION OF CFTR-F508DEL BY THE E3 LIGASE RNF19B AND
THE UBIQUITIN E2 CONJUGATING ENZYME UBE 2L6
Introduction
CF is the most common, lethal autosomal recessive disease caused by a mutation in the
gene encoding CFTR [7, 139]. CFTR is a cAMP regulated chloride channel that is a member of
the ABC superfamily. The most common mutation amongst CF patients is the deletion of the
phenylalanine residue at position 508 (CFTR-F508del). CFTR-F508del (F508del) is unable to
achieve a native, folded state that is required for the protein to export from the ER to the apical
membrane of epithelial cells [8]. F508del is synthesized in the ER, and it is trapped in the ER
because it is unable to obtain its native state [15, 19, 20, 140]. It is polyubiquitinated, translocated
to the cytosol and is eventually degraded by the 26S proteasome [9, 19, 141]. This network is
generally called ERAD [66]. Studies have previously shown that F508del has a folding defect that
can be adjusted by chemicals to promote proper folding and introducing channel function at the
plasma membrane [9, 11, 19]. The ER folding pathway of CFTR is tightly coordinated with the
ERAD pathway whereby misfolded CFTR are targeted to the cytosolic proteasome [142]. This is
extremely important because pharmacological agents that may help with F508del folding or the
blocking of its degradation may help CF patients.
A small amount of F508del can return to its proper folding pathway with the help of
correctors, such as VX-809 [143, 144]. Experimental restoration of F508del trafficking to the
plasma membrane results in partial function of the chloride channel, raising therapeutic
speculations [9, 11]. The UPS is essential in the degradation of F508del. Ubiquitin is covalently
attached to F508del by an isopeptide linkage between the c-terminal glycine of ubiquitin and
amino group of lysine of the substrate (F508del). This is done through a cascade system, which
consists of E1 activating enzyme, E2 conjugating enzymes, and E3 ligase enzymes [145].
Ubiquitination of F508del occurs when the E3 ligase binds to the F508del and E2 enzyme that is
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thioesterifed with ubiquitin [90, 146], and brings both to close proximity so that ubiquitin is
transferred from the E2 to the substrate [21]. Ubiquitin E3 ligases are important enzymes that
transfer ubiquitin from an E2 ubiquitin-conjugating enzyme to the mutant CFTR. E3 ligases are
important for they show substrate specificity for ubiquitin transfer to the target proteins. To date,
there are little studies in mammalian cells that identify E2 conjugating enzymes and ER-localized
E3 ubiquitin ligases that function in the degradation of F508del.
About 60% of newly synthesized wild type-CFTR (WT-CFTR) and almost 99% of F508del
is degraded by the UPS [17]. Therefore, there seems to be specific checkpoints set in place within
the ER that allows F508del to stray apart from its WT counterpart during early stages of CFTR
biogenesis. We believe that ER resident E3 ligases and there corresponding E2 conjugating
enzymes are the initial checkpoint proteins that may be responsible for the divergence of WTCFTR and F508del during CFTR biogenesis.
Previous studies have identified the E3 RMA1 and the E2, UBC6e cooperate to degrade
both CFTR and F508del. [22, 24] However, there seems to be other mechanisms that facilitate
F508del degradation because these studies still illustrate a significant amount of F508del that is
being degraded, even when the above-mentioned proteins were silenced. The E2 UBCH5 forms
an E3 complex with CHIP and the E3 ligase Hdj2 to ubiquitinate F508del [13, 20, 22]. When this
complex is destroyed, F508del is still not able to traffic out of the ER, but instead is degraded.
Therefore, other E2/E3 complexes may exist in F508del degradation and other mechanisms need
to be sorted out to determine other potential therapeutic approaches to help prevent F508del
degradation.
Through a literature search of E2 conjugating enzymes that seem to interact with ER
membrane-bound E3 ligases, we discovered the E2 conjugating enzyme UBE 2L6, whom has its
role in the ubiquitin conjugating pathway[147-149] This E2 interacts with RING E3 ligases that
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are bound to the ER such as RNF122, RNF19B, and also RNF19A[150]. This is important because
it has already been shown that certain E3 ligases, such as RMA1, acts in the ER membrane to
identify the misfolded F508del [24]. We were able to determine that the E2 UBE2L6 was a key
player in F508del degradation, and its interacting E3 ligase, RNF19B, also mediates F508del. In
this study, we explore the possible roles of UBE 2L6 and the E3 ligase RNF19B in the proteasomal
degradation of F508del. We determined that both proteins degraded F508del when overexpressed.
Also, when both proteins were knocked down through siRNA-mediated silencing in HBE cells,
there was an increase in expression of F508del, which was further enhanced when treated with
VX-809. The same cells treated with VX-809 also had more chloride channel activity at apical
membrane of the cells. Our results provide a clearer landscape of the molecular mechanism that
underlies the proteasomal degradation of F508del through UBE 2L6 and RNF19B.
Methods
Antibodies and chemicals
Mouse monoclonal anti-CFTR antibody was obtained from University of North Carolina
at Chapel Hill. Rabbit polyclonal actin and polyclonal anti-NA/K ATPase were purchased from
Cell Signaling. Mouse monoclonal UBE 2L6 antibody were acquired from Research Diagnostics
Inc. Mouse monoclonal Myc, HA, and His-tag antibodies were bought from Abcam. VX-809 and
MG132 were obtained from Selleck Chemicals, GlyH101 was obtained from Calbiochem,
Forskolin,3-Isobutyl-1-methylxanthine (IBMX) and cycloheximide (CHX) were purchased from
Sigma. siRNA was purchased through Dharmacon Inc.
Cell culture and drug treatment
CFBE-F508del expressing cell line was established from CFBE41o− (CFBE), a wellcharacterized human airway epithelial cell line. CFBE cells was derived from the bronchial
epithelial cells of a CF patient with cftr F508del/F508del genetic background and with no
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detectable expression of the mutant protein. CFBE-F508del cells were cultured in MEM with 10%
fetal bovine serum addition of 0.5 μg/L puromycin. All cells were maintained in a humidified
atmosphere containing 5% CO2 at 37 °C. Confluent cells were treated with VX-809 in culture
medium at the designated concentration for 24 h. Cells were harvested after 24 h treatment. HEK
293 cells were cultured in DMEM with 10% fetal bovine serum.
Plasmid constructs, DNA constructs.
F508del in pcDNA3.1 vector was described previously [26]. The UBE 2L6 and RNF19B
cDNA sequence was amplified by PCR and inserted into pcDNA3.1(+) at EcoR1 and EcoRV sites.
HA-ubiquitin was purchased from Addgene.
Immunoblotting
Cells were lysed by sonication in lysis buffer (50 mM HEPES, 150 mM NaCl, 1 mM
EDTA, 1% NP40, 10% glycerol and protease inhibitors cocktail). Specifically, protein samples
were resolved by SDS-PAGE and transferred to PVDF membranes, which were blocked at room
temperature for 1 h with 5% (w/v) non-fat milk in TBST (10 mM Tris (pH 8.0), 150 mM NaCl,
0.05% Tween 20). The blots were incubated with primary antibodies in TBST with 10% fetal
bovine serum at room temperature for 2-3 h. The blots were then washed three times with TBST
and incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h, followed by
three washes with TBST. The reactive bands were visualized by incubation with enhanced
chemiluminescence substrates (PerkinElmer Products) and exposure to X-ray film (Eastman
Kodak Co).
Co-immunoprecipitation (Co-IP) for ubiquitin assay
Cell lysate treated with MG132 in Lysis buffer ( (50 mM HEPES (pH 7.4), 150 mM NaCl,
1 mM EDTA, 1% NP-40, 10% glycerol) was precleared with protein A/G-Sepharose beads
(Invitrogen). The precleared lysate was mixed with 10ug of the indicated antibody and 25ul of
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protein A/G-Sepharose beads and incubated overnight at 4ºC with gentle rotation.
Immunocomplexes were resuspended in SDS sample buffer and subjected to SDS-PAGE gel and
immunoblotting.
Cycloheximide (CHX) chase analysis
After 24 h treatment with designated reagent, cells were continued to be cultured in
medium supplemented with 50 μg/ml CHX and harvested at designated time points. Cell extracts
were subjected to the immunoblotting analysis with appropriate antibodies.
Biotinylation and pulldown of CFTR on streptavidin beads
After treatment with specified reagent of 24 hours, cells were washed 3 times with PBS
and exposed to 0.5mg/ml in PBS EZLink Sulfo-NHS-LC--biotin (Thermo Scientific) for 1 h on
ice. Cells were washed 3 time with PBS, quenched with 100mM glycine in PBS, and rinsed 2 time
again. Then cells were solubilized by sonication in RIPA buffer (150 mM NaCl, 1 mM Tris/HCl,
0.5% (w/v) deoxycholic acid, 1% (w/v) NP-40, 0.1% SDS, 2 mM EDTA, 50 mM NaF and protease
inhibitors). The resulting lysate was centrifuged at 21100 g for 10 min at 40C, and supernatant
protein content was determined using protein assay dye reagent (Bio Rad). The supernatant was
incubated with streptavidin beads for overnight at 40C. After a brief centrifugation the supernatant
was removed, the beads were washed 4 times with lysis buffer. Pull-downed proteins were
resolved by SDS-PAGE, transferred to PVDF membranes and performed an immunoblot as
described above.
Ussing chamber experiments
CFBE-F508del cells grown on collagen-coated transwell filters (Costar, 0.33 cm2, 0.4-μm
pore) were polarized and treated with indicated reagent 24h. Filters were mounted in Ussing
Chambers (Physiologic Instruments #P2300). The basolateral bathing solution consisted of 120
mmol/L NaCl, 25 mmol/L NaHCO3, 3.3 mmol/L KH2PO4, 0.8 mmol/L K2HPO4, 1.2 mmol/L
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CaCl2, 1.2 mmol/L MgCl2 and 10 mmol/L d-glucose. The apical bathing solution replaced 120
mmol/L NaCl with 120 mmol/L Na glutamate to achieve a transepithelial chloride gradient. The
bathing solutions were maintained at 370C and gassed with 95% O2, 5% CO2 to retain a pH 7.4.
Short-circuit current and transepithelial resistance were measured continuously using a voltageclamp (VCC-MC8) and Acquire and Analyze v2.3 data acquisition hardware and software
(Physiological Instruments, San Diego, CA, USA).
Filters were equilibrated for approximately 15 min to permit electrical parameters to
stabilize, and baseline short circuit current (ISC) was measured. 10 μM forskolin and IBMX was
added to the basolateral chamber to activate and remain CFTR-mediated anion secretion. After 3
min and currents had reached steady state 10 μM/L CFTR inhibitor Glyh 101 was added to the
apical solution. Stop record after currents had achieved steady-state. Changes in short-circuit
currents were calculated from the mean currents obtained during the 20-s period.
Confocal microscopy
Immunofluorescence staining of filter-grown cells was performed as described previously
[26]. Briefly, CFBE-F508del cells were fixed in 4% paraformaldehyde and permeabilized with a
mixture of 4% paraformaldehyde and 0.1% Triton X-100. The cells were then washed three times
with buffer A (0.5% BSA and 0.15% glycine at pH 7.4 in phosphate-buffered saline). After
blocking with purified goat serum, the monolayers were incubated in the appropriate primary
antibodies (anti-Myc 1: 300, and anti-CFTR217 1:300) for 1 hour followed by three washes in
buffer A and subsequent incubation with fluorescein isothiocyanate (green) or rhodamine (red)labeled secondary antibodies (1:1000, Molecular Probes) for another hour. After washing with
buffer A, the filters were mounted on glass coverslips using synthetic resin and subjected to
confocal microscopy. Collected images were exported to ImageSpace (Molecular Dynamics) for
subsequent reconstruction and processing.
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Quantitative real-time reverse transcription PCR analysis
Total cellular RNA was extracted using TRIzol reagent and reverse-transcribed to cDNA
using a random primer. The real-time PCR reaction mixture containing cDNA template, primers
and SYBR Green PCR Master Mix (Invitrogen) was run in a 7,500 Fast Real-time PCR System
(Applied Biosystems). Fold changes of mRNA levels were determined after normalization to
internal
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Data analysis
The immunoblot images were scanned at 600 dpi for densitometry analysis using Image J
software. The Values are means ± SEM. Statistical signiﬁcance of differences was determined
using paired two-tailed Student’s t-test.
Results
RNF19B is a candidate in F508del degradation
To identify which ER resident E3 Ligase maybe involved F508del degradation, we
performed a siRNA screen on ER resident E3 ligases on HBE cells (Figure 1A, 1B). The screen
illustrated that RNF19B, when knocked down, increased the expression of F508del. Therefore, we
determined that RNF19B may be a candidate in F508del degradation [152]. RNF19B is a Ring
finger protein family of E3 ligases, which interacts with E2 conjugating enzyme(s) and substrates,
facilitating the transfer of an activated ubiquitin to the substrate [153, 154]. RING finger E3 ligases
have a RING structure that is involved in ubiquitinating its substrate. To show that this site is
involved in ubiquitinating F508del, we generated a catalytically non-functioning RNF19B RING
mutant where we mutated a cysteine residue at position 119 to a serine residue (c119s) to disable
the

RING

domain.

HEK
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Figure 1. E3 ubiquitin ligase siRNA library screen: A. HBE cells, CFBEF508del cells, were transfected
with 30 nM of the indicated siRNA. The blot shows CFTR B-band expression. B. Quantification of CFTR
B-Band/Actin intensity of the E3 ligase siRNA screen (mean  SE, n = 3, p < 0.05).

and with Myc-RNF19B or with Myc-RNF19B c119s (Figure 2A). Overexpressing Myc-RNF19B
causes F508del degradation. When transfected with the catalytically non-functioning mutant,
Myc-RNF19B c119s, F508del is expressed to similar levels as control (Figure 2A, 2B). To
determine if RNF19B ubiquitinates F508del, HEK293 cells were first transfected with F508del
and with Myc-RNF19B plasmid. 24 hours post-transfection, HA-ubiquitin was transfected into
these cells. The cells were than harvested and CFTR was pulled down (Figure 2C). The left panel
demonstrates that there is more HA-ubiquitin immunoprecipitated with F508del when RNF19B
was overexpressed compared to control. The right panel demonstrates that total CFTR was the
same between both conditions under MG-132 treatment. If RNF19B regulates F508del, they
should be located in the same compartment. To determine if these proteins are localized within the
same

area

of

the

cell,

CFBE-F508del

cells

were
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Figure 2. RNF19B ubiquitinates F508del and colocalizes with F508del in the ER. Stable HEK293 cells
were co-transfected with F508del and with either Myc tagged RNF19B or Myc tagged RNF19B mutant
(RNF19B c119s). B. Quantification of panel A. C. HEK 293 cells were transfected with F508del plasmid
and control or Myc-RNF19B plasmid. 24 hours later, these cells were transfected with HA-Ubiquitin. Cells
were harvested and CFTR (217) was immunoprecipitated. HA-ubiquitin was immunoblotted. Input was
immunoblotted with the indicated antibodies. Conditions were all under MG132 treatment. (mean  SE, n
= 3, p < 0.05 D. F508del-CFBE cells were transfected with Myc tagged RNF19B and immunostained for
Myc (green) and F508del (red). Nuclei were stained blue. Scale bar 50 μm.

transfected with Myc-RNF19B and then immunostained with Myc (green) and F508del (red)
(Figure 2D). The immunostaining shows that Myc-RNF19B is localized with F508del in the
perinuclear area, which is indicative of the ER. To determine how RNF19B affects the half-life
of F508del, we performed a cycloheximide-chase where HEK 293 cells were co-transfected with
F508del and with the control or with Flag-RNF19B for 48 hours. The cells were than treated with
50µg/ml cycloheximide for the different indicated time periods. (Figure 3A, 3B). Overexpressing
RNF19B decreased the half-life of F508del from 60 minutes to about 20 minutes, suggesting
RNF19B participates F508del degradation.
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Figure 3. RNF19B over-expression accelerates F508del-CFTR degradation. A. Cyclohexamide (CHX)
experiments were performed on HEK 293 cells co-transfected with F508del and with a control or with Flag
tagged RNF19B for 48 hours. The cells were then treated with CHX (50 µg/ml) for the indicated times. B.
The level of remaining F508del at different time points was quantified as the percentage of initial F508del
level (0 min of CHX treatment). RNF19B expression resulted in a shorter half-life of F508del. (mean  SE,
n = 3, p < 0.05).

Silencing RNF19B in HBE cells rescues F508del
To determine if RNF19B has any effect on F508del, CFBE-F508del cells were transfected
with siRNA against RNF19B. When knocking down RNF19B, there is an increase in F508del
protein expression almost 3-fold (Figure 4A). Due to the lack of a sufficient antibody to RNF19B,
silencing of RNF19B expression was confirmed by RT-PCR (Figure 4B). We overexpressed a
Myc tagged RNF19B (Myc-RNF19B) plasmid into CFBE-F508del cells and transfected these
cells with siRNA against RNF19B (Figure 4C, 4D) to determine knockdown of RNF19B in HBE
cells. The knockdown of RNF19B increased endogenous F508del by about 3-fold in CFBEF508del cells (Figure 4C, 4D). Next, HEK 293 cells were co-transfected with Myc-RNF19B and
F508del (Figure 4E). 0.5 μg of RNF19B decreases F508del by about 1.4-fold, whereas transfection
with 1.0 μg of RNF19B decreases F508del by about 4.7-fold (Figure 4E, 4F), indicating RNF19B
degrades F508del in a dose-dependent manner.
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Figure 4. Silence of RNF19B increased F508del Expression and RNF19B mediates F508del
degradation in a dose-dependent manner A. Silence of endogenous RNF19B expression using siRNA
increased F508del expression by about 3-fold in CFBE-F508del c ells. B. Quantification of mRNA
expression levels of RNF19B in CFBE-F508del cells with RNF19B knocked down using siRNA. C.
Silence of overexpressed RNF19B expression using siRNA increased endogenous CFTR-F508del by
approximately 3-fold in human airway epithelial cells. D. Quantification of panel C. E. HEK293 cells were
stably transfected with Myc-tagged RNF19B. F. Quantification of CFTR-F508del expression level from
panel E. (mean  SE, n = 3, * =p < 0.05, **= p < 0.01).

F508del function is enhanced by RNF19B knockdown in the presence of VX-809 treatment
To further determine if RNF19B is involved F508del degradation and its function, we
needed to determine if CFTR trafficking to the plasma membrane is affected by RNF19B. We
performed biotinylation experiments to determine if more F508del traffics to the plasma
membrane when RNF19B is silenced (Figure 5A). Knockdown of RNF19B promotes F508del C-
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band to the plasma membrane to act as a chloride channel. When RNF19B is knocked down with

Figure 5. Silence of RNF19B promotes VX-809-mediated F508del trafficking to the plasma
membrane and enhances F508del-CFTR function. A. Biotinylation experiment illustrating that
silencing endogenous RNF19B in CFBE-F508del cells using siRNA increased F508del C-band expression
to the plasma membrane compared to control and even more so with 3µM VX-809 treatment. B.
Quantification of panel A. C. Ussing Chamber experiments. CFBE-F508del cells were first treated
indicated siRNAs for 48hrs and then incubated with 3 µM VX-809 for additional 24 hrs in 6.5 mm
transwells. Short-circuit currents were retrieved through the Ussing chamber and F508del currents were
determined through the treatment with the indicated conditions. Forskolin/IBMX (10µM) and GlyH101
(10µM). D. Quantification of short-circuit currents. (mean  SE, n = 3, p < 0.05).

VX-809 treatment, there is a 1.8-fold increase in C-Band (Figure 5A, 5B). To determine if there
is enhanced F508del function when RNF19B is knocked down, we performed Ussing Chamber
experiments. We transfected CFBE-F508del cells with siRNA against RNF19B or a scramble
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siRNA as a control. 48 hours post-transfection, we treated the cells with either 3 μM VX-809 or
with DMSO for 24 hours. 24 hours post-treatment, cells were set up in the Ussing chamber to
measure short-circuit currents. Short-circuit currents demonstrated that compared to control,
RNF19B knocked down in CFBE-F508del cells increased short-circuit currents by about 3.25
µA/cm2 compared to scramble controls when stimulated by forskolin and IBMX (Figure 5C, 5D).
There is an increase of about 7.7 µA/cm2 in CFTR function when CFBE-F508del cells have
RNF19B knocked down and treated with VX-809 compared to scramble control (Figure 5C,5D).
This set of data indicates that there is rescue F508del protein and function when RNF19B is
silenced in HBE cells.
Overexpressing UBE 2L6 degrades F508del
Through a literature search, we were able to discover UBE 2L6 interacts with many E3
ligases that were found in the ER [150]. Interestingly, through the literature search we were able
to determine that RNF19B is a partner of UBE 2L6 [152]. This interaction with E3 ligases in the
ER may mediate F508del degradation; therefore we wanted to observe what happens to CFTR
when we overexpress UBE 2L6. We used HEK 293 cells and co-transfected with F508del and
UBE 2L6 for 48 hours. 48-hours post-transfection, total protein lysates were harvested and probed
for F508del levels by immunoblot analysis. Overexpressing UBE 2L6 decreased F508del
expression by about 2.5-fold (Figure 6A, 6C).
To further confirm UBE 2L6 effects on degrading F508del, we developed a dominantnegative mutant of UBE 2L6 where a cysteine residue at position 86 was mutated to a serine
residue (UBE 2L6 DN). This mutation will destroy the catalytic activity of UBE 2L6 and therefore
the activated ubiquitin is not able to transfer onto the E2. Hence, theoretically the ubiquitin is not
able to transfer to the misfolded protein. We transiently transfected HEK 293 cells with F508del
and with UBE 2L6 or UBE2L6 DN or a control (pCMVꞵ) (Figure 6B). Consistent to previous

29
finding, overexpressing UBE 2L6 decreases F508del. When UBE 2L6 DN is overexpressed,
F508del expression increases 1.9-fold (Figure 6B, 16C). These data suggest that UBE 2L6
facilitates F508del degradation by ubiquitination.

Figure 6. UBE 2L6 over-expression increase F508del degradation. A. HEK 293 cells were cotransfected with CFTR-F508del and control or Flag-UBE 2L6 plasmid. Cell lysates were subjected to
immunoblot. Compared to the control, UBE 2L6 overexpression increased F508del degradation. B. HEK
293 cells were co-transfected with F508del and the plasmids that are listed above. Cell lysates were
subjected to immunoblot. Compared to control, UBE 2L6 increased F508del. The dominant negative
mutant, Flag-UBE 2L6-DN, decreased F508del degradation. Flag-UBE 2L6-DN plasmid was developed
by mutating the cysteine at position 86 to a serine. C. Quantification of CFTR C-Band/Actin when FlagUBE 2L6 or Flag-UBE 2L6 DN is overexpressed. (mean  SE, n = 3, p < 0.05).

Silencing UBE 2L6 in HBE cells with VX-809 rescues F508del
We next wanted to determine if we can rescue F508del if we silenced UBE 2L6 in human
bronchiole epithelial (HBE) cells. We used cystic fibrosis HBE cells that have the F508 mutation
(CFBE-F508del) and knockdown UBE 2L6 with siRNA. 48 hours post-transfection, the cells were
treated with VX-809 or with DMSO as a control for 24 hours. VX-809 is a drug used in the CF
field that folds F508del so that the protein is to traffic to the plasma membrane [143]. 24 hours
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post-treatment, the cells were harvested and probed for CFTR and actin. When UBE 2L6 was
knocked down with siRNA, there is a 2.8-fold increase in F508del expression, which is illustrated
as Band-B (Figure 7A, 7C). Band B is the misfolded CFTR that is trapped in the ER where it will
be eventually degraded by the proteasome in the cytosol. Interestingly, with VX-809 treatment,
there seems to be a 2.7-fold increase in C-band expression of CFTR compared to control (Figure
7A,

Figure 7. Silencing UBE 2L6 in F508del-CFBE cells decrease F508del degradation. A.
Represented blot shows silence of endogenous UBE 2L6 expression using siRNA in cells CFBEF508del following 3 μM VX-809 treatment increased immature F508del (B band) and rescued mature
F508del-CFTR (C Band). B. Quantification of knockdown of UBE 2L6. C. Quantification of CFTR
B-Band/Actin when UBE 2L6 is knocked down with or without VX-809 treatment. D. Quantification
of CFTR C-Band/Actin when UBE 2L6 is knocked down with or without VX-809 treatment. (mean 
SE, n = 3, p < 0.05).
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7D). This is critical in that this shows that with UBE 2L6 knocked down, there seems to be a
greater pool of B-band CFTR. With this increased pool of B-band, VX-809 helps more F508del to
traffic to the plasma membrane.
F508del function is increased with UBE 2L6 knockdown and VX-809 treatment
To investigate how UBE 2L6 affect CFTR function, we used the Ussing chamber to
measure F508del function by measuring forskolin-stimulated short-circuit current in HBE cells.
We transfected CFBE-F508del cells with siRNA against UBE 2L6 or a scramble siRNA as a
control. 48 hours post-transfection, we treated the cells with either 3 μM VX-809 or with DMSO
for 24 hours. 24 hours post-treatment, cells were set up in the Ussing chamber to measure shortcircuit currents. A representative trace of the short-circuit currents demonstrates that compared to
control, UBE 2L6 knocked down in CFBE-F508del cells, there is a slight, but significant increase
in CFTR function by about 2.9 µA/cm2 when stimulated by forskolin and IBMX (Figure 8A, 8B).
When CFBE-F508del cells have UBE 2L6 knocked down and treated with VX-809, there is an
increase in CFTR function by about 5.4 µA/cm2 compared to cell transfected with scramble siRNA

Figure 8. UBE 2L6 knockdown enhances F508del function. A. Ussing Chamber experiments. CFBEF508del cells were first treated indicated siRNAs for 48 hrs and then incubated with 3 µM VX-809 for
additional 24 hrs in 6.5 mm transwells. Short-circuit currents were retrieved through the Ussing chamber
and F508del currents were determined through the treatment with the indicated conditions. Forskolin/IBMX
(10 µM) and GlyH101 (10 µM). B. Quantification of short-circuit currents. (mean  SE, n = 3, p < 0.05).

32
and treated with VX-809 (Figure 8A, 8B). The quantification of three experiments illustrates that
knockdown of UBE 2L6 and VX-809 treatment had a significantly greater increase in F508del
function compared to controls (Figure 8B).
Discussion
Here, we have identified an E2 conjugating enzyme, UBE 2L6 that mediates the
proteasomal degradation of F508del. We’ve found that when UBE 2L6 is knocked down in human
airway epithelial cells and treated with VX-809, there is an increase in expression of CFTR Cband, the functional form of CFTR. UBE 2L6 works as a conjugating enzyme, acting as a transient
holder of activated ubiquitin to be ready to tag a substrate [155], in this case misfolded F508del.
We have shown that by mutating UBE 2L6 so that it cannot carry that activated ubiquitin, there is
an increase is expression of F508del, therefore demonstrating that UBE 2L6 does indeed mediate
the degradation of F508del through the ubiquitin proteasome system. Also, this shows that UBE
2L6 is an important player in the F508del degradation because the mutation to UBE 2L6 rescues
F508del to similar levels as seen in control. Therefore, there is a greater pool of F508del that can
be used on by VX-809 to allow for greater trafficking of the misfolded protein to the plasma
membrane. Future studies will be focusing on developing and discovering small inhibitors to act
as a drug to inhibit UBE 2L6 function so that there is a greater pool of F508del protein for VX809 to act on. VX-809 will help fold F508del so that is can traffic to the plasma membrane.
With the increase in F508del pool, we also showed that there is an increase in CFTR
function when UBE 2L6 in knocked down. Using human airway epithelial cells, we knocked down
UBE 2L6 and determined that there was an increase CFTR function when forskolin and IBMX
was added to the cells. Importantly, when the same cells that had UBE 2L6 knocked down were
treated with VX-809, there was a greater CFTR function compared to control. These experiments
further support the idea that when UBE 2L6 is knocked down there is a greater pool CFTR protein
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that VX-809 can work on. Interestingly, previous studies have shown that UBE 2L6 conjugates
with valosin-containing protein (VCP) during aberrant protein turnover [156]. VCP is a key
component of the ERAD system, forming the Derlin-1/VCP/VIMP complex [81, 157]. VCP
recognizes and process ubiquitinated substrates with cofactors such as p47, and UBXD1 [158160]. The ATP-driven unfolding activity of VCP provides the force to extract substrates out of the
ER membrane so that they can be degrade by the proteasome. We have already shown that VIMP,
a linker between Derlin-1 and VCP in the ERAD complex, utilizes and E3 ligase, RNF5 to direct
F508del for proteasomal degradation [161]. RNF5 interacts with the E2 conjugating enzyme
Ubc6e to degrade F508del, not UBE 2L6.
We have also shown that RNF19B, an E3 ligase that interacts with UBE 2L6, mediates the
degradation of F508del. Interestingly, RNF19B is localized in the endoplasmic reticulum [162,
163], where F508del is localized. Our data also demonstrates that VX-809 treatment RNF19B
knocked down in HBE cells, there is an increase in F508del function at the plasma membrane.
This is similar to what was seen when performing similar experiments with UBE 2L6. This is
important in that not only does UBE 2L6 aids in the degradation of F508del, but that it interacts
with and ER localized E3 ligases to assist in this degradation. Therefore, this is a potential early
checkpoint in CFTR degradation because these two proteins that are involved in the ubiquitin
proteasome system prevent F508del from trafficking to the plasma membrane to act as a chloride
channel. If we are able to use small inhibitors to prevent these proteins from ubiquitinating
F508del, we will be able to provide the cell with greater pool of F508del that is not degraded by
the proteasome but allow VX-809 to act on more F508del so that it is able to traffic to the plasma
membrane. Synergy between the knockdown of UBE 2L6 and RNF19B with VX-809 treatment,
which enhanced F508del chloride secretion, indicates that these two proteins may offer a
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therapeutic approach for CF. This allows for more chloride channels to the plasma membrane that
will be extremely beneficial to CF patients.
Previous studies have shown that RMA1 and Ubc6e are involved in the proteasomal
degradation of F508del [24]. There have been other E3 ligases that have been implicated in
F508del degradation including CHIP, gp78, Hrd1, Nedd4-2, and RNF185[95-99]. RNF5 acts to
degrade F508del contranslationally, while CHIP acts posttranslationally [24].

RNF19B is

homologous, structurally to RNF5, therefore we predict that RNF19B, with its interacting partner
UBE 2L6, also degrades F508del contranslationally, however further studies are needed to confirm
this. Based on the data presented, we propose the following mechanism that is involved by
F508del degradation. Quality control checkpoints within the ER senses the misfolded F508del due
to the F508del mutation. The misfolded F508del is brought into association with RNF19B and
UBE 2L6 where both the E3 and E2 proteins cooperate to ubiquitinate F508del. The ubiquitinated
F508del is than signaled to proceed to the proteasome for degradation.
F508del the most common mutation amongst CF patients, where these patients lack the
functional form of CFTR to act as an anion channel[1]. With this mutation, therapeutic strategies
that create the mature form of CFTR partially restores the function of CFTR at the apical
membrane of cells. Previous work in our lab have shown that with VIMP knockdown significantly
enhances the rescue effect of CF corrector VX-809[161]. This was similar to what was seen in this
current study when RNF19B and UBE 2L6 were knocked down. Previously, CF therapeutic
discovery was governed by a one-step rule, where chemicals were discovered either as a corrector
for mutated CFTR or as an activator or inhibitor to increase or decrease CFTR-associated protein
expression [164-167]. With the expansion of classification of CFTR mutation, and with our study,
we suggest a two-step rule: First, prevent F508del from ERAD. Second, help the rescued F508del
to fold and migrate to the cell surface to function as a chloride channel. This study presents
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RNF19B and UBE 2L6 as potential targets for preventing early degradation of F508del, which
may be important in the development of efficient therapies to treat CF.
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CHAPTER 4: FUNCTION DEFECT OF CFTR ABSENCE IN RABBITS
Introduction
Mutations of cftr gene lead to cystic fibrosis (CF), one of the most common life-threating
autosomal recessive disorders in Caucasian population [28]. The disease is unique because it
affects multiple organs with lung dysfunction contributing the most of the morbidity and the
mortality [168-171]. There have been major progress in the understanding of CF pathogenesis
since CFTR gene was cloned in 1989; however, many important questions remain unanswered [7].
Animal models are extremely demanded to understand human diseases CF animal models have
undoubtedly contributed to the understanding CF pathogenesis and to test and develop therapeutic
reagents, yet the existing models have their limitations, either because the animal models fail to
reproduce major phenotypes observed in CF patients [102] or because the animal models are of
very high maintenance costs and special animal cares [108].
In this study, we report the generation and characterization of rabbit models of CF, in
consideration that human and rabbit share considerable anatomical and physiological similarities
[132]. The amino acid sequence of rabbit CFTR has approximately 93% identity to that in human,
which is the highest among all animals utilized to generate CF animal models. Our work show that
disruption of CFTR gene in rabbits produces human-like Cystic Fibrosis rabbits which include
spontaneous lung infections. The CF rabbit models may serve as a useful tool for this devastating
disease.
Dr. Xu’s lab at the University of Michigan developed a robust CRISPR-Cas9 based geneediting platform in rabbits. To produce CFTR knockout (KO) rabbits, they first designed sgRNAs
based on the CFTR exon 11 sequence. They tested the targeting efficiency of five different
sgRNAs (sg-01 to -05) in vitro by microinjecting the different amount of individual sgRNAs and
Cas9 RNA to pronuclear stage embryos and analyzed the editing efficiency using the blastocysts.
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Among the five sgRNAs tested, sgRNA-02 was found the most effective. They next used sgRNA02 for microinjection and performed embryo transfer. 162 embryos were transferred to 6
recipients, 11 live kits were obtained, and 3 kits were confirmed as CFTR F0 KO founders. The
data presented here were from CF rabbits with one nucleotide deletion, which generated the stop
codon at amino acid position 478.
Methods
Statement of animal care and use
All animal maintenance, care and use procedures were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) of Wayne State University (WSU), the
University Committee on the Use and Care of Animals of the University of Michigan. Rabbits
were generated at the UM and Wayne State.
Production of CFTR mutant rabbits
Dr. Xu’s lab at the University of Michigan developed a robust gene-editing platform in
New Zealand White rabbits based on CRISPR/Cas9 [172-174]. Using this system, embryo
microinjection followed by embryo transfer was performed to produce 3 CFTR mutant founder
rabbits. Off-target effects of the guide RNA (sgRNA-02) in all three founders were tested by PCR
amplification of the top 20 potential off-target sites. Upon sexual maturation (5-6 months), F0
mutant founders were bred with wild-type (WT, i.e., CFTR+/+) animals to establish the F1
generation of heterozygous (CFTR+/-) rabbits. F1 animals were then inbred to obtain CFTR-/(“CF”) rabbits. Confirmation of CFTR knock-out was tested by electrophysiology,
immunohistochemistry, and Western blotting.
Animal husbandry
The animals utilized in this study were produced at two locations, primarily to monitor
electrophysiology and improve animal husbandry. At two weeks of age, the dam and kits were
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given Golytely (an osmotic laxative, Braintree Labs, Braintree MA) to drink rather than water. The
CF rabbits consumed this laxative for their entire life. At 4 weeks of age all kits were given
Bioserve (Bio-Serve, Frenchtown, N.J.) in a bowl 2x/day as a supplement in addition to their
regular rabbit chow (Teklad Global rabbit diet(230), Envigro, Madison WI). At weaning, the CF
kits were given Bioserve in a bowl 1x/day as a supplement for their entire life. At 1 week of age
all CF rabbits are weighed and abdominally palpated every other day for abdominal masses. If
masses were detected, rabbits were treated twice a day with: 1) 50ml SQ warmed physiological
saline; 2) PO 0.5 mg/kg cisapride (increases motility of lower gut; 3) PO 0.5ml/kg simethicone
(anti-gas agent); 4) PO 0.5 mg/kg metoclopramide (increases motility of small bowel); and 5) PO
0.5 ml/kg lactulose (a laxative). Treatment continued until masses resolved. NOTE: Some of the
older CF rabbits presented multiple times with gut symptoms which were reversed with our
treatment protocol.
Animal phenotyping
Survival analyses was conducted by careful monitoring of animal mortality across time. In
general, histological analyses were conducted using tissue collected in 10% neutral formaldehyde
solution followed by paraffin embedding and staining (details in figure legends). Special stains are
provided in the figure legends. The lung phenotype was further characterized by collection of
bronchoalveolar lavage fluid followed by bacterial culture and cytology. The microbiome of
selected samples was monitored by 16S RNA sequencing. Short-circuit current recordings in
Ussing chambers were conducted on tracheal preparations [175-177].
Immunoblotting
Fresh lung tissues of CF and WT rabbits were harvested after euthanasia, homogenized in
lysis buffer ((50 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 10% glycerol
with protease inhibitors cocktail (Roche 11836145001)) and centrifuged for 10 minutes at 10, 000
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rpm, 40C. The concentration of total protein was tested by using protein assay dye reagent (BioRad, 500-0006), and then, 50mg protein was resuspended in 6×SDS sample buffer and denatured
at 420C for 10 minutes. Protein samples were resolved by SDS-PAGE and transferred to PVDF
membranes, which then were blocked at room temperature for 1 hour with 5% (w/v) skim milk
powder in TBST (10 mM Tris (pH 8.0), 150 mM NaCl, 0.05% Tween 20). The blots were
incubated with primary antibodies (596, 1: 5000 in TBST with 10% fetal bovine serum (FBS),
from J. Riordan, University of North Carolina at Chapel Hill) at room temperature for 1 hour. The
blots were then washed four times with TBST and incubated with horseradish peroxidaseconjugated secondary antibodies (1:5000, Abcam) in TBST with 10% FBS for 1 hour, followed
by five washes with TBST. The reactive bands were visualized by incubation with enhanced
chemiluminescence substrates (PerkinElmer Products) and exposure to X-ray film (Eastman
Kodak Co). CFBE-o41 WT-CFTR cell lysate was used as the positive control.
Immunofluorescence
Lung lobes of CF and WT rabbits after euthanasia were perfused with 4% neutral
paraformaldehyde (in 1×PBS, pH7.2) at a constant hydrostatic pressure and fixed in 4% neutral
paraformaldehyde for 24 hours. Tissues were then cut into 0.5cm-thick pieces and gradually
dehydrated in 5% ， 20% ， 30% sucrose solutions. Next, tissues were sectioned into 10µm
thickness slices using a Cryotome. The tissues were then washed three times with buffer A (0.5%
BSA and 0.15% glycine at pH 7.4 in phosphate-buffered saline). After blocking with purified goat
serum, the sections were incubated with the appropriate primary antibodies (anti-CFTR 596, gift
from University of North Carolina, http://cftrantibodies.web.unc.edu/, 1:300) for 1 hour followed
by three washes in buffer A and subsequent incubation with fluorescein rhodamine -labeled
secondary antibodies (1:300, Molecular Probes) for another hour. After washing with buffer A, the
section was incubated with diluted DAPI solution for 5 minutes at room temperature, followed by
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mounting with an anti-fade mounting media and imaged by confocal microscopy.
Short-circuit recorded by Ussing chamber
Tracheal preparations were prepared as 4 cm long sections of CF and WT rabbits that were
excised and immediately placed into Ringer’s Buffer (120mM NaCl, 25mM NaHCO3, 3.3mM
KH2PO4, 0.8 mM K2HPO4, 1.2mM MgCl2, 1.2mM CaCl2, and 10mM glucose.) with 10 µM
indomethacin, that was continuously gassed with 95% O2 and 5% CO2 for 10 minutes. After
incubation, the trachea was placed under a dissection microscope and connective tissues were
removed. A longitudinal cut was made along the trachea, exposing the mucosal side. The tracheal
epithelium was carefully placed on a slider with an exposed surface area of 0.20 cm2. Both sides
of the epithelium were perfused with equal amounts of Ringers’ Buffer at 37ºC. Both sides of the
chamber were gassed with 95% O2 and 5% CO2, providing gas lift circulation. Each sample was
equilibrated under voltage clamp (short circuit, Isc) conditions for 20 minutes. Once incubation
period was completed and a basal Isc was achieved, amiloride was added to the apical side of the
chamber to a final concentration of 10-5 M. Once a new steady-state was reached, forskolin was
added to the basal side of the chamber, at a final concentration of 10-5 M. Once a new steady
steady-state was achieved, GlyH101 was added to the apical side of the chamber to a final
concentration of 10 µM. Once a new steady-state was achieved, bumetanide was added to the basal
side of the chamber to a final concentration of 10 µM. After a new steady-state was achieved, the
tissue was allowed to re-equilibrate for 20 minutes and the experiment was completed. The Ussing
chamber was an EM-CSYS-8 from Physiological Instruments.
General histology staining
Tissues were fixed in 10% neutral formaldehyde solution in PBS (pH7.2) for ~ 24 hours,
embedded into paraffin blocks, and cut in to 10 µm sections.
For Hematoxylin and eosin (H&E) staining, after deparaffinization, sections were stained
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in Mayer’s hematoxylin solution for 8 minutes, and eosin-phloxine solution for 30 seconds to 1
minute. Sections were rinsed by running tap water between the two steps. After dehydration,
sections were mounted with xylene based mounting medium.
For PAS staining, deparaffinized tissue sections were oxidized in 0.5% periodic acid
solution for 5 minutes, stained with Schiff reagent for about 15 minutes, and washed in running
water for about 5 minutes. After counterstaining in Mayer's hematoxylin for 1 minute, sections
were washed in running water for 5 minutes. After dehydration, sections were mounted with
xylene based mounting medium.
For Alcian blue staining, deparaffinized tissue sections were stained with Alcian blue for
15 minutes and then stained with Schiff's reagent for 10 minutes. After staining nuclei with
haematoxylin, sections were mounted.
Collagen staining was achieved by using Gomori’s trichrome stain kit (87020, Thermo):
deparafnized sections were placed in 40ml of Bouin’s Fluid in a plastic coplin jar with a lid applied
loosely and incubated at 560C in a water bath for 1 hour. Sections were rinsed in running tap water
for 5 minutes until the yellow color was removed. Sections were placed in Working Weigert’s iron
hematoxylin (solution A: B=1:1) and stained for 10 minutes. Sections were rinsed in running tap
water for 10 minutes, stained in trichrome stain for 15 minutes, and then individual sections placed
in 1% acetic acid solution for 1 minute and rinsed in deionized water for 30 seconds. Sections were
mounted after dehydration.
Bronchoalveolar lavage (BAL) fluid collection
Rabbits were mounted on an operating table with ventral sides up after euthanasia. Neck
and chest skin were shaved and disinfected with 70% alcohol. A 2cm longitudinal incision was
made at the neck to expose the trachea, and a 15cm piece of suture thread was placed underneath
the trachea. A 3cm PE tubing (4mm) on a three-way connector was inserted ~ 2.5 cm into the

42
trachea directed towards the lung. The tubing was secured in the trachea by tying with a suture. A
syringe loaded with sterile PBS was attached to one side of the three-way connector for lavage.
Lung was lavaged three times with 2 ml, 2 ml and 1 ml of sterile PBS and using a new syringe
each time.
BAL bacterial plates
300 µl fresh BAL was deposited on typic soy agar (TSA, BD 236950), Columbia ANA SB
(BD 221928), Columbia CNA (BD 221352) and Chocolate II (BD 04082), and PSA (BD 292710)
plates and cultured for 48 hours at 37 0C.
BAL cytology
To perform the total WBC cell counts in BAL fluid, 10 µl BAL was loaded into a
hemocytometer. Four corner squares of the hemocytometer were counted, and WBC cell count
were calculated using the formula below:
Total WBC cells/ml = Total WBC cell count in 4 squares X 2500
For quantification of neutrophils, 150 µl BAL sample were loaded onto Cytospin slides
(StatSpin and Iris, Chatsworth, CA, USA). Samples were cytocentrifuged at 1,000 rpm for 2 min.
The cells deposited on the slide were air-dried and stained with Wright’s stain (Sigma- Aldrich).
In each case, more than 200 total cells were counted, and the percentage of neutrophils was
calculated as the ratio of total #neutrophils/total counted cells.
16S RNA sequencing
The V4 region of 16S rRNA gene was amplified by PCR, where primers contained a unique
barcode to distinguish specimens. The PCR amplicons were checked by agarose gel
electrophoresis to ensure the product base pair length were as predicted and no non-specific
amplification bands were present. Then PCR amplicons underwent high throughput sequencing
using HiSeq 2500 rapid-run mode, which generated 250 bp paired-end reads.
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In data analysis, we first removed adapters, PCR primers and low quality bases from each
read.

The

data

quality

was

identified

using

Fastqc

software

(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and the low quality bases were
removed by USEARCH tool (www.drive5.com/usearch). Because the total read length (250nt ´ 2)
is longer than the PCR amplicon, the mate read pairs (ie, forward- and reverse-read) overlapped,
and the USEARCH tool was used to identify the overlap region and merge the mate pairs. Second,
the taxonomy assignments based on sequence alignments were computationally resolved using
QIIME software (www.qiime.org). This analysis involves constructing Operational Taxonomic
Units (OTUs) based on sequence similarity within the reads, picking a representative sequence
from each OTU. We employed a hybrid approach: firstly, sequences were assigned to operational
taxonomic units (OTUs) and clustered into phylotypes according to their similarity to previously
annotated sequences in reference databases; secondly, the unmapped reads were used to construct
OTUs by clustering sequences de novo, purely based on their similarity.
Results
CFTR functional expression in the GI tract, growth curves, and survival
In rabbits, CFTR is widely expressed in the GI tract, including the jejunum and colon. The
loss of CFTR in the GI tract results in failure to gain weight normally in CF subjects and in a small
percentage of CF newborns, it can cause death due to meconium ileus [178-181].
The impact of the loss of CFTR function on the growth kinetics of CF vs. WT rabbits was
assessed. At birth, CF rabbit kits had no significant differences in body weight or appearance
compared to WT littermates (Figure 9F). CF kits failed to gain weight at the same rate as their WT
counterparts after one month of age, a feature typical of CF children (Figure 9A, 9F).
Administration of a laxative, Golytely, and a liquid supplement (Bio-Serv, cat. no. F1147SP)
significantly improved the weight gain of CF rabbits. However, they did not approach the growth
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rate of the WT controls (Figure 9F).

45
Figure 9. Characterization of CF respiratory tract expression and function. A. Overall appearance of
WT (+/+) and a CFΔ1 (-/-) rabbit at 44 days of age, illustrating the smaller size of CF rabbits as compared
to WT littermates. B. Immunostaining of CFTR in tracheas from a WT and a CF rabbit, representative
micrographs for differential interference contrast (upper panels) and immunofluorescence (lower panel).
Scale bar 50 μm C. CFTR western blots for normal human CFBE cultures alongside tissue lysates from CF
and WT rabbit tracheas. D. A representative trace of a Ussing Chamber experiment of freshly excised rabbit
trachea for a 1 WT rabbit and 1 CF rabbit E. Freshly excised rabbit tracheal short circuit currents (Isc)
measurements in Ussing chambers. Isc changes in response to amiloride (10-4 M, apical), forskolin/Ibmx
(10-4 and 10-5 M, basolateral, respectively), GlyH101 (10 µM, apical), and bumetanide (10-4 M, basolateral)
are shown. N = 3 WT and 3 CF rabbits *p < 0.05 different vs. WT.F. Body weight with age for WT rabbits
(black), untreated CF rabbits without treatment (blue), and CF rabbits treated with Golytely starting at 2
weeks of age (red). *p < 0.05 vs. untreated CF. G. Survival for WT and heterozygous rabbits (black, n=190),
CF rabbits on Golytely (blue, n=23, and CF rabbits on Golytely, BioServe, and abdominal palpationdirected GI therapy (orange, n=38).

New Zealand White rabbits have a lifespan (7-10 years) that is comparable to both pigs
and ferrets [182]. Survival curves showed that CF rabbits on a standard laboratory diet had a
median age of survival, i.e., t1/2, of 44 days, significantly lower than their WT littermates (P<0.01;
Figure 1G). The median survival of CF rabbits was significantly increased to t1/2 66 days when
Golytely and a liquid diet were administered (P<0.01). It was possible to detect intestinal
stasis/obstruction in pre-weaning CF rabbits (2 weeks) by routine abdominal palpation, and a
protocol was developed to administer a “cocktail” of mucokinetic agents if intestinal masses were
detected. This cocktail was effective ~ 70% of the time to eliminate palpable masses and restore
weight gain. Rabbits treated with this regimen lived on average > 80 d (Figure 9D), significantly
exceeding the lifespan of large animal CF models [103, 118, 183]
CFTR expression and function in rabbit lungs: loss of function in CF rabbits
CFTR protein expression was next examined in the tracheas from CF vs WT rabbits. Like
human bronchial epithelia (HBE), robust CFTR band B and C expression were observed in WT
rabbits (Figure 9C). In contrast, western blot analysis failed to detect CFTR protein in the tracheas
of CF rabbits. Immunofluorescence was also used to detect rabbit CFTR using the CFTR-596
antibody [184]. CFTR was localized to the apical membrane of WT rabbit tracheal epithelial cells,
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whereas no tracheal epithelial CFTR expression was detected in CF rabbits (Figure 9B).
For bioelectric characterization of CFTR lower airway function, Ussing chambers were
employed to measure short-circuit currents (Isc) across CF and non-CF tracheas (Figure 9D, 9E).
Addition of forskolin and isobutylmethylxanthine (IBMX) to stimulate CFTR produced an
increase in Isc in the WT but not CF rabbits. Similarly, apical addition of the CFTR inhibitor,
GlyH-101, decreased Isc in WT but not CF rabbits. Finally, basolateral addition of bumetanide, an
inhibitor of the Na+-K+-2Cl- cotransporter, decreased Isc in the WT tracheas but not CF tracheas.
These results established the functional loss of CFTR-mediated anion secretion in the CF rabbit
trachea.
As noted above, amiloride is a blocker of epithelial Na+ channel (ENaC) mediated Na+
absorption. As shown in Figure 9E, the amiloride-sensitive current was greater in CF than WT
rabbits, consistent with accelerated Na+ absorption. However, given the interactions between Na+
and Cl- conductance’s in determining the magnitude of amiloride responses, isotope fluxes are
required to confirm whether Na+ absorption is absolutely increased in CF rabbit tracheas [185,
186].
Structural abnormalities in CF rabbit respiratory systems
Like CF mice and pigs [103, 187-189], CF rabbit tracheas lacked the concentric ring pattern
characteristic of their age matched WT counterparts (Figure 10A). With Alcian blue staining, the
WT trachea showed complete cartilage ring formation with regular sizes and shapes (Figure 10B).
In contrast, the CF tracheas exhibited irregular sizes and shapes, irregular cartilage rings, and thin
bands of smooth muscle and fused cartilage (Figure 10B).
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Figure 10. Malformation of
tracheal cartilaginous rings in CF
rabbits. A. Gross images of the
tracheas from WT and CF rabbits.
The tracheas from CF rabbits do not
exhibit concentric and equally
spaced cartilaginous rings as
observed in WT rabbits. B.
Representative micrographs of
tracheal longitudinal sections from
two WT and two CF rabbits stained
with Alcian Blue, illustrating the
aberrant shape and organization of
cartilaginous
rings
in
CF
specimens.

CF rabbit lung disease: mucus accumulation
A major phenotype in CF subjects is defective airways mucociliary clearance [190, 191].
There is debate as to whether CF lung disease is initiated by large airway SMG dysfunction or
defects in superficial epithelial mucus hydrating functions of small airways [105, 106, 183, 192194]. The rabbit is an ideal species to study this issue because it lacks SMGs and like humans, but
unlike rodents, expresses CFTR throughout distal (small) airway epithelia.
We visually observed the accumulation of mucus (i.e., mucus plugs) in the airways of
young (~ 40 d) CF rabbits (6 out of 30 examined, 20%). Mucus plugs were discovered in the
trachea (Figure 11A), bronchi (Figure 11B), and in the bronchioles of CF rabbits (Figure 11C), but
none in airways of the WT animals (Figure 11D, 11E).
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Figure 11. Mucus accumulation
and inflammation in the lower
airways of CF vs WT rabbits. (AB) Mucus extracted from freshly
excised CF trachea and bronchus.
Scale bar 0.5 cm. C. ABPAS/Hematoxylin
staining
of
intraluminal material in CF rabbit
bronchiole. Scale bar 20μm. (D-E)
Low and high-power H&E stained
micrograph of WT rabbit airways.
Scale bar 100 and 50μm,
respectively. (F-G) CF rabbit airway
wall (F, scale bar 20μm) illustrating
submucosal inflammatory infiltrates.
Higher power AB-PAS staining of
goblet cells in the airway epithelium
(G, Scale bar 10μm). (H-J)
Inflammation in CF kit lungs,
including intraluminal neutrophils (I,
J, scale bar 50 and 10 μm,
respectively). (K-L) Bronchusassociated lymphoid tissue in CF kit
airway wall. Scale bar Scale bar 100
and
20μm,
respectively.
M.
Percentage of neutrophils in CF vs
WT rabbit bronchoalveolar lavage.
Mean +/- SD. p < 0.05 different vs.
WT. N. Total BAL white blood cell
(WBC) count. Mean +/- SD.

Consistent with the importance of the superficial epithelium in rabbit lung
pathophysiology, histologic staining revealed metaplastic/hyperplastic and distended goblet cells
in the airways of CF as compared to WT rabbits (Figure 11F, 11G). In addition to mucus
accumulation, inflammatory responses, including large numbers of neutrophils (Figure 11H-J) and
macrophages in the lumen in parallel with submucosal bronchus-associated lymphoid tissue
(BALT, Figure 11K, 11L) were observed in CF but not WT r abbits. Like neonatal human
bronchoalveolar lavage (BAL) data [195, 196], the neutrophil percentage but not total cell number
was significantly higher in CF vs. WT rabbit BAL (Figure 11M, 11N). Collectively, these data
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mimic those of neonatal/young CF children who have increased airway mucus and inflammation
[195, 197].
CF rabbit lung disease: spontaneous bacterial infection
To quantitate the incidence and identify the type of bacteria found in rabbit lungs, CF and
WT rabbits were euthanized (median age 43 d) and BAL harvested. Culture of some CF BAL on
TSA, ANA, CNA and Chocolate agar plates produced colony growth of anaerobes, facultative
aerobic bacteria, gram-positive cocci, and gram-negative bacteria (Figure 12A). Overall, 13 out of

Figure 12. Characterization of bacteria in bronchoalveolar lavage (BAL) from CF vs. WT rabbits.
A. CF vs WT BAL cultured on TSA, ANA, CNA and Chocolate plates. The plates were incubated in 37 0C
for 48 hrs. B. 16S rRNA sequence analysis of bacteria species in BALF from five CF rabbits.
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66 (19%) CF rabbits tested had positive BAL cultures for bacteria. None of the WT BALs (n=39)
produced positive colonies on any plate (Figure 12A). 16S r RNA gene sequence analysis of five
infected CF rabbits revealed polymicrobial species, including Streptococcus, Micrococcaceae,
Enterobacteriaceae, Staphylococcus, and Stenotrophomonas (Figure 12B).
Pseudomonas aeruginosa was cultured (Figure 13A) in two CF rabbits who became
moribund and were sacrificed at > 60 days of age (64 and 141 days, respectively). Grossly, the

Figure 13. Characterization of bacterial infection in bronchoalveolar lavage (BAL) from a moribund
CF rabbit and WT age-matched control. A. BALs were plated on Pseudomonas aeruginosa identification
selective agar (TSA) and allowed to grow for 48 hours. Growth and progressive pigment development
indicated the presence of P. aeruginosa in the CF specimen. B. Gross appearance of lungs from a wild-type
and CF rabbit with P. aeruginosa infection. Note the mottled and inflated appearance of the left lobe in CF
rabbit as compared to WT control. In each lung, the right lobes were subjected to BAL. C. The un-lavaged
left main stem bronchus contained intraluminal mucus with visible black fibers and greet dots, suggestive
of bacterial macrocolonies and/or aspirated material.
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lungs of one Pseudomonas aeruginosa-infected female CF rabbit exhibited a pale color with
mottled discoloration, whereas the lungs of its WT littermate had a normal healthy appearance
(Figure 13B). The left lobes of this rabbit were not lavaged and revealed that the left main stem
bronchus was filled with mucus containing Pseudomonas macrocolonies associated with aspirated
food (Figure 13C).
Discussion
The rabbit was selected as a CF model because it provides fidelity of CFTR expression in
the lung with respect to humans, exhibits high CFTR homology to human CFTR, and exhibits
sensitivity to potentiators developed for CF pharmacotherapy. Important other features include the
well-known breeding performance of rabbits, early weaning (~ 2-months of age), a size
intermediate between current models, and relatively inexpensive housing costs.
The current CRISPR-derived indel genetic modifications of rabbit CFTR offer practical
model for studies of CF pathogenesis and therapy. One practical feature of the rabbit is that female
CF rabbits are fertile, making the generation of adequate rabbit numbers feasible. A second
practical feature is that untreated CF rabbits do not exhibit the perinatal meconium ileus and
mortality observed in the mouse and large animal models with a median survival of 44 days. The
average lifespan could be extended to > 80 days with addition of a simple oral osmotic
laxative/liquid diet and physical examination-based pharmacologic interventions.
There has been debate about the relative importance of large airway submucosal glands
(SMG) vs small airways (no SMG) in the initiation of CF lung disease. In human CF, the first
detectable abnormalities in lung pathology, radiology, and pulmonary function appear to be in the
small airways [198-201]. However, these airways are more difficult to study in humans because
of their protected/distal nature. The rabbit lung exhibits an architecture that resembles human small
airways, including the absence of SMG, with a substantial club cell population [202]. Importantly,
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unlike mice, the rabbit expresses CFTR like humans throughout distal airway regions.
Studies of human CF infant/children on a timed, i.e., yearly basis, have emerged from the
AREST CF cohort [203, 204]. AREST CF data have revealed that early CF lung disease is
heterogeneous within the lung with a relatively small fraction of CF neonates/young children
exhibiting bacterial infection by 3 years of age. Indeed, a muco-inflammatory environment is the
first detectable event in the human CF lung, followed by infection by anaerobes and subsequently
the classical CF pathogens, including Pseudomonas [203]. Similar timed protocols likely can be
performed in future studies of CF rabbits but not in this early observational study focused on
improving survival. However, we did identify visible mucus in the airways of CF rabbits and
histological sections in ~ 11% of the CF rabbits by ~ 40 days that was accompanied by an increase
in BAL neutrophil numbers/percentages. This visual analysis likely underestimated the mucus
content in the lungs, as evidence from the AREST CF study suggests that most mucus from young
CF subjects is manifest as small mucus plaques/plugs harvested as ~ 10-100 µm “flakes” by BAL
[205].
A spectrum of culture technologies designed to capture anaerobic, microaerophilic, and
aerobic bacteria were employed to characterize lower airway bacterial infection in this study. An
~ 19% incidence of bacterial infection was noted in CF rabbits. Importantly, these infections were
polymicrobial and dominated by anaerobic/microaerophilic bacteria. This polymicrobial infection
and incidence rate mimicked data from the human AREST cohort [203]. Notably, the only two
incidences of Pseudomonas aeruginosa infection occurred in older animals, typical of CF children.
It should be noted that the CF rabbits were housed in a SPF facility that reduced/eliminated the
possibility of intercurrent viral infections. In contrast, the AREST CF children had experienced
multiple lower respiratory tract viral infections prior to/during the observational AREST study
[206]. Thus, the next steps to test the relevance of CF rabbits to early human CF lung disease are
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to raise rabbits in non-SPF environments and/or expose them to intermittent lower airway viral
infections.
With respect to lower airways pathogenesis, the bioelectric properties of both the upper
and lower airways in the CF rabbit mimic the typical bioelectric properties of human CF subjects.
Namely, there was a virtual absence of forskolin-mediated anion secretion. Further, there was
evidence for persistent and/or indeed raised sodium absorption (amiloride-sensitive PD/Isc) in both
regions. As noted, ion fluxes will be required to confirm this notion. Regardless, the absence of
anion secretion, coupled with persistent or, indeed, raised sodium transport, is predicted to
dehydrate the airway surface environment, causing mucus hyperconcentration, mucus adhesion,
and subsequent inflammation/bacterial infection [203, 205]. Importantly, the findings in the rabbit
suggest the CF pathologic cascade can be mediated exclusively by the small airways epithelium
in the absence of SMG defects.
Conclusion and Future Directions
In summary, this study elucidated a molecular mechanism that is involved in F508del
degradation and introduced a new animal model that mimicked human CF.
We found additional proteins that are involved in F508del degradation, and possible targets
for therapeutic intervention. The E2 conjugating enzyme UBE 2L6, and its’ interacting E3 ligase,
RNF19B, both mediate the proteasomal degradation of F508del. Also, our data demonstrates that
VX-809, an already established processing drug treatment, operates to enhance F508del function
at the plasma membrane when UBE 2L6 and RNF19B are also silenced. Therefore, modulation of
UBE 2L6/RNF19B mediated degradation of F508del offers a promising area for therapeutic
intervention.
This study also introduces the CF rabbit model to the CF research community as an
intermediate size model that is relevant to human CF pathogenesis and therapy. It manifests both
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airway and GI phenotypes that are common to humans which are relatively easily measured for
studies of CF pathogenesis. The CF rabbits also exhibit straightforward readouts of CFTR function
for pharmacotherapy/genetic therapy, including: 1) lower airways bioelectric, infection, mucus
plugging, and inflammation; and 2) abnormal weight loss and survival. Future improvements in
animal husbandry may make the rabbit model even more useful, including gut-corrected rabbits
and G551D rabbits that may be maintained on potentiators.
Interestingly, UBE 2L6 is highly expressed in human lung tissue, compared to other organs
[207]. Therefore, future studies will look into using the CRISPR/Cas9 system to knock in F508del
mutation into rabbits and examine the expression level of UBE 2L6 in F508del rabbits compared
to WT rabbits. It will be interesting to see if F508del knock-in rabbits have a higher expression of
UBE 2L6 in the lungs compared to WT rabbits. The higher expression may result in a swifter
degradation of F508del protein, contributing to a severe lung phenotype that may be comparable
to human CF. This same tactic can be used to investigate RNF19B expression levels in the lungs.
Previous studies in mice tissue showed that several E3 ligases, including RNF19B, was
upregulated by ER stress [208]. F508del that is retained in the ER activates the unfolded protein
response, a form of ER stress [209], therefore RNF19B expression in the lungs may also be
upregulated. Therefore, future studies in the rabbit model may try to highlight targeting the UPR
in airway inflammation and target the UPR as a therapeutic strategy for CF related airway disease.
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Cystic Fibrosis (CF) is the most common, lethal autosomal recessive disorder, and is
caused by mutations in the cystic fibrosis transmembrane conductance regulator protein (CFTR),
an anion channel that is found in most epithelial cells lining the airway and gut. The most common
mutation of CFTR is deletion of phenylalanine at position 508 (CFTR-F508del), which produces
a misfolded protein. Through the ubiquitin proteasome system (UPS), this misfolded protein is
ubiquitinated and signaled for degradation via the cytosolic proteasome. Previous studies
demonstrating experimental restoration of F508DEL-CFTR trafficking to the plasma membrane
showed partial function of the chloride channel, raising therapeutic speculations. Some
components of how F508DEL-CFTR is degraded is known, however many mechanisms that
underlie its degradation through ERAD and the UPS is still unknown. In the first part of the study
we used a siRNA screen to discover the E3 ligase, RNF19B, and its interacting partner, UBE 2L6
mediates F508del degradation. We used siRNA-mediated silencing of endogenous UBE 2L6 and
RNF19B in the CF human bronchial epithelial (HBE) cell line to demonstrate that there is an
increase in F508del-CFTR expression. We also co-expressed UBE 2L6 and RNF 19B with
F508del in HEK293 cells that demonstrated a decrease in F508del compared to control.

78
Cycloheximide-chase (CHX) experiments using HEK 293 cells overexpressing RNF19B and
F508del showed that there was a decrease in F508del half-life. Lastly, using siRNA-mediated
silencing of endogenous UBE 2L6 and RNF19B in CFBE-F508del cells increased forskolinstimulated short-circuit currents.
Cell models have given the CF research community a tremendous amount of information
about the mechanisms that underlay the disease. However, they are not suited to understand the
pathophysiology of the disease. Existing animal models of CF have limitations because they either
fail to exhibit key CF pulmonary phenotypes, die soon after birth, and/or require special care with
high maintenance costs. In the second part of the study, we report the generation by CRISPR/Cas9
of CF rabbits, a model with a relatively long lifespan and affordable maintenance and care costs.
CF rabbits untreated live for > 40 d, and therapeutic regimens directed towards restoration of
intraluminal transit of gastrointestinal materials extend lifespan to > 80 days. CFTR expression in
the rabbit lung mimicked expression in the human lung with widespread expression in proximal
and distal lower airway epithelia. CF rabbits exhibited human-like abnormalities in airway
bioelectric properties and sporadic, spontaneous polymicrobial lower respiratory tract infections
in the absence of submucosal glands. The CF rabbit model may serve as a useful tool for
understanding CF pathogenesis and the practical development of therapeutics for this lifeshortening disease.
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